INTRODUCTION
The KIT proto-oncogene encodes for a class III transmembrane receptor tyrosine kinase that is composed of an extracellular portion containing five immunoglobulin-like domains and an intracellular portion consisting of a juxtamembrane and two protein tyrosine kinase domains (PTK1 and PTK2) split up by an interkinase domain.
1,2 Activating mutations in KIT have been reported in AML and are confined to either the extracellular (exon 8 mutations) [3] [4] [5] and the PTK2 domain (D816 mutations) 6 . Both classes of KIT mutations have been identified predominantly in specific genetic subgroups of AML: exon8 mutations in patients with inv (16) , and D816 mutations in patients with t(8;21). In both AML subgroups one of two parts of the transcription factor CBF is targeted: AML1 (CBFα) in t(8;21), and CBFB (CBFβ) in inv (16) leading to the common nomenclature of "Core binding factor leukemia" for inv(16)/t(16;16) and t(8;21) positive AML. The clinical and prognostic significance of KIT mutations in AML is unclear. Preliminary data suggest that KIT exon 8 mutations are associated with an increased relapse rate 4 and KIT-D816 mutations were correlated to a higher WBC count in AML patients 7, 8 .
On the molecular level the translocation (8;21) leads to the generation of the AML1-ETO fusion gene 9 which has been shown to influence differentiation, proliferation, and apoptosis in both in vitro and in vivo models and promotes self-renewal in retrovirally transduced primary human CD34+ cells. 10 The t(8;21)/AML1-ETO positive AML is commonly associated with a favourable prognosis. [11] [12] [13] [14] Recently, it was postulated that fusion genes involving transcription factors, are not sufficient to induce leukemia and require additional "cooperative" mutations that trigger proliferation. In line with this hypothesis it has been shown that activating mutations of the gene for tyrosine kinase FLT3 cooperate with PML-RARA to induce leukemia in mice. 15 only.
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In contrast, the significance of additional genetic alterations in patients with t(8;21)/AML1-ETO positive AML are poorly studied.
In the present study, we report that KIT-D816 mutations define an unfavourable subgroup in patients with AML1-ETO positive AML. Thus, KIT-D816 mutations represent a reliable molecular marker identifying patients with a poor prognosis in an otherwise prognostically favourable AML group. As implied by in vitro experiments, patients that are positive for AML1-ETO as well as for KIT-D816 mutations might benefit from new innovative therapeutical strategies, e.g. KIT-selective specific PTK inhibitors.
MATERIALS AND METHODS

Patients
Patient samples were referred to the Laboratory for Leukemia Diagnostics between 1998 and 2004. All samples underwent a standardized processing including central sample registration, preparation, and evaluation by cytomorphology, cytochemistry, multiparameter immunophenotyping, cytogenetics, fluorescence in situ hybridization, and molecular genetics. [16] [17] [18] Prior to therapy, all patients gave their informed consent for participation in the AMLCG studies. All samples investigated in this study were obtained at the time of diagnosis.
Bone marrow samples were used when available; otherwise, peripheral blood was used.
Selection criteria were limited to the availability of sufficient material and participation in the above mentioned clinical trials. Thus, de novo as well as secondary and therapyrelated AML were included. Patient characteristics are summarized in 
Treatment protocol of the German AMLCG-Study
Eighty percent of the analyzed patients were treated according to the AMLCG studies.
Treatment comprised the randomized comparisons of TAD9/TAD9 versus TAD9/HAM (AMLCG1992), and of TAD9/HAM versus HAM/HAM (AMLCG1999) double induction therapy followed by TAD9 consolidation. Patients with APL were treated according to the respective APL protocol of the AMLCG. 19 Patients in complete remission after TAD9 consolidation were subsequently randomized for monthly maintenance therapy or S-HAM as a second course of consolidation (AMLCG1992) or autologous stem cell transplantation (AMLCG1999).
The study design adhered to the declaration of Helsinki and was approved by the ethics committees of the participating institutions prior to its initiation.
Polymerase chain reactions (PCR) at diagnosis
PCR for AML1-ETO fusion transcript were performed as has been described. 20 For each sample an ABL specific RT-PCR was performed to control the integrity of RNA as has been described. 21 Strict precautions were taken to prevent contamination. Water instead of cDNA was included as a blank sample in each experiment. Amplification products were analyzed on 1.5% agarose gels stained with ethidium bromide.
Screening assay
Mononucleated cells were isolated by standard Ficoll-Hypaque density gradient centrifugation. Nucleic acid isolation and cDNA synthesis was performed as described before 21 . Screening for KIT-D816 mutations was performed using a melting curve based
LightCycler assay with forward primer KIT816F: CAGCCAGAAATATCCTCCTTACT, 
Sequence analysis
All cases that were found to be positive were confirmed by sequence analysis. Approximately 100 ng of purified PCR products were directly sequenced with 3.3 pmol of each forward and reverse primer using the Big Dye Terminator Cycle Sequencing Kit (Applera, Darmstadt, Germany). After initial denaturation at 95°C for 5 minutes, 25 cycles at 94°C for 15 seconds and 60°C for 4 minutes were performed. Sequence analysis was performed on an ABI 310 or 3100 Avant sequence detection system (Applied Biosystems, Foster City, USA).
Cell proliferation of Ba/F3 cells and application of specific PTK inhibitors
IL-3 dependent Ba/F3 cells stably expressing either KIT-WT or KIT-D816V were seeded at a concentration of 0.05 x 10 6 /mL in the presence or absence of IL-3 and SCF, as described previously. 5 The cells were initially treated with the indicated PTK inhibitors imatinib, PKC412 (both kindly provided by Novartis) and SU5614 (purchased from Calbiochem 
RESULTS
Frequency of KIT-D816 mutations in AML samples
A total of 1940 patients were screened for KIT mutations in exon 17 of the tyrosine kinase domain 2. Patient characteristics are summarized in table 1. Of the total cohort, 1614 patients had de novo AML, 201 secondary AML (s-AML) after MDS and 125 therapy-related AML (t-AML). All patients were screened for mutations in exon 17 at and around codon Asp816 in the KIT receptor. In 33 patients (1.7%), a mutation affecting codon 816 of the KIT gene was detected ( Fig. 1) . Characteristics of all cases with KITD816 mutations are given in table 2. Sequencing of the mutations revealed a gac to gtc exchange (Asp to Val) in 21 patients, a gac to tac exchange (Asp to Tyr) in two and a gac to cac exchange (Asp to His) in one sample. The mutation of 9 patients that were found positive for a D816 mutation by melting curve analysis could not be sequenced due to the presence of less than 10% of mutated cells in the sample.
There was no significant difference with respect to de novo AML, AML after MDS prephase or t-AML after preceeding malignancy. For personal use at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From spectively, Figure 2A ). In contrast, the frequency of KIT-D816 mutations was significantly lower in patients with a t(15;17) (0/84 patients = 0%) and a complex karyotype (1/236 =0.4%).
Frequency of KIT-D816
We next analyzed additional cytogenetic alterations that were found in KIT-D816 positive patients. Of 33 patients with a KIT-D816 mutation, ten had a normal karyotype (30.3%), eight a t(8;21) (24.2%), two an inv(16) (6.1%), one a complex aberrant karyotype (3.0%), four patients a trisomy 4 (12.1%), and eight had other rare aberrations (Table 2). The frequency of KIT-D816 mutations was significantly associated with t (8;21) and with trisomy 4, as assessed by Fisher's exact test. This finding is in line with previous reports on the association with KIT mutations in CBF leukemias with these cytogenetic aberrations. 26, 27 .
Based on the tight association of t(8;21) and KIT-D816 mutations we further examined the frequency of other translocations involving the AML1 gene (rare t(AML1)) in patients with a KIT-D816 mutation: four patients had a translocation with AML1 other than t(8;21) (4/33; 12.1%). In detail these were two cases with a t(3;21)/AML1-EVI1 (cases 8 and 9
in 
Activating mutations of receptor tyrosine kinases are associated with distinct cytogenetic subgroups
Experimental data from mouse models have suggested that certain mutations of RTK cooperate with distinct leukemic fusion genes to induce leukemia in mice. 28, 29 To validate this hypothesis in patients with AML, we analyzed the frequency of activating mutations in the FLT3 and KIT gene in different cytogenetic subgroups. As shown in Figure   2B , the frequency of KIT-D816 mutations in patients with AML1-ETO positive leukemias was higher than in patients with normal and complex aberrant karyotypes. 
Prognostic significance of KIT-D816 mutations
Analysis of the prognostic significance of KIT-D816 mutations was carried out a) for 64 patients with t(8;21) and b) for 663 patients that were classified to the subgroup with intermediate prognostic karyotypes ( fig. 3 ). The median overall survival (OS) of t(8;21) patients without KIT-D816 mutations was 1836 days in contrast to 304 days for the KIT-D816 positive subgroup (Fig. 3a) (p=0.0006) . Regarding event-free survival, the median was 244 days for the KIT-D816 mutation positive patients and 744 days for the nonmutated subgroup (p=0.0027) (Fig. 3a) . Other significant parameters on survival in the group with t(8;21) were age (p=0.021), but not FAB subtype, etiology and leukocyte counts. Thus, the negative impact of KIT-D816 mutations was found to be independent of age (p<0.001).
The same analysis was conducted for patients with a prognostically intermediate karyotype (Fig. 3b) and for all unselected de novo AML (Fig. 3c) . In contrast to the t(8; survival curves were compared using double sided log rank test.
Sensitivity of KIT-D816V and KIT-WT to different PTK inhibitors
The activating KIT-D816V mutation is reported to be resistant to the selective PTK inhibitor imatinib that inhibits wildtype and juxtamembrane mutants of KIT.
30
To test the sensitivity of the KIT-D816 mutant to different selective PTK inhibitors, the cDNAs for KIT-WT and KIT-D816V subcloned in pMSCV-IRES-eYFP mammalian expression vector were stably transfected in Ba/F3 cells as described before. 5 In addition to imatinib, we used PKC412 and SU5614 that have been reported to inhibit KIT-WT. 23, 31 We carried out proliferation assays in the presence and absence of these three inhibitors (Fig. 4A) . As described previously, the KIT-D816V mutant was resistant to imatinib (IC 50 In order to further investigate the mechanism by which the compounds used in our study inhibit the proliferation of transformed Ba/F3 cells, we conducted cell cycle and apoptosis analyses using propidium iodide staining (Fig. 5) . After treatment of 24h with PKC412, both, SCF stimulated KIT-WT cells as well as KIT-D816V transduced cells underwent a rapid increase in the percentage of apoptotic cells that was dose-dependent ( Fig. 5A and C) . Conversely, treatment with imatinib only led to a rise in the number of apoptotic nuclei in KIT-WT cells whereas cells with KIT-D816V were absolutely resistant to this compound up to high doses. In both cell lines PKC412 induced a significant accumulation of cells in G 1 /G 0 phase (Fig. 5B and data not shown) . Surprisingly, no G 1 /G 0 arrest was observed in SCF stimulated KIT-WT cells that were treated with increasing doses of imatinib (data not shown), although this compound significantly increased the number of apoptotic nuclei (Fig. 5A ). This result, however, is congruent with the reported fact that some small cell lung cancer cell lines responding to imatinib are slowed in G2/M phase but are not arrested in G 1 /S phase. 33 only.
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These data indicate that PKC412 has significant inhibitory activity against KIT receptors carrying a point mutation at Asp816 and might be of therapeutical benefit in patients with inferior prognosis AML1-ETO/KIT-D816V+ AML. 15 . In contrast, core binding factor leukemias have been described to frequently have KIT mutations 6 .
While KIT exon 8 mutations were frequently described in CBFB-MYH11 positive AML 3, 5 we provide evidence that KIT-D816 mutations represent important cooperative mutations in AML1-ETO positive. Despite an overall low frequency of KIT mutations in AML they were found relatively frequent in AML1-ETO positive AML. Importantly, these mutations are associated with a poor prognosis in AML1-ETO positive AML but not in patients with a normal karyotype.
Despite the relatively high frequency of 10.5 % (8 of 76 patients with t(8;21)) KIT-D816 mutations in t(8;21) positive AML detected in our cohort, an even higher frequency of 40% (6 of 15 patients with core binding factor leukemias) and 17% (9 patients of 54 with t(8;21)) was described in previous studies 7, 8 . This may be based on different ethnic only.
For personal use at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From background or by different selection criteria. Patients treated within the AMLCG study are relatively old (median age 60 years in the present cohort). It was already described that the frequency of cytogenetic subgroups differs between younger and elderly AML 8, 36 .
In t(8;21)/KIT positive AML the AML1-ETO depicts the so-called class II mutation that leads to a block in differentiation, whereas the KIT mutation represents the class I mutation that triggers excessive proliferation of the aberrant cell clone. An optimal cooperation of these two mutations could be postulated as it could be shown that t(8;21) with KIT-D816 mutation had a significantly worse outcome compared to those without KIT-D816 mutations. The data presented in our study point to a tight association of KIT-
D816 mutations and t(8;21) whereas other RTK mutations, FLT3-LM and FLT3-TKD
were more frequent in samples with t(15;17) and normal karyotype. For personal use at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From study, these patients could also be considered for treatment with specific PTK inhibitors like PKC412.
An association of trisomy 4 in t(8;21) positive AML with KIT-D816 mutations has been described previously. 37, 38 KIT is localized on chromosome 4 and thus trisomy 4 leads to an increased gene dosage of KIT. The Kasumi-1 cell line that is positive for AML1-ETO carries trisomy 4 and an amplification of KIT could be shown. 39 The mechanism of an elevated mutation rate is still unclear but has previously been described also for MLL-PTD in trisomy 11 40 and AML1-mutations in trisomy 21. 41 The elevated mutation rate might be due to an upregulation of the KIT gene at the genomic level which has recently been described for seminomas. Thus, this non-hematopoietic malignancy has some striking parallels to AML positive for KIT-D816 mutation: the relevant gene is duplicated by a trisomy of the respective chromosome, one point mutation occurring is homologous to KIT-D816 and the disease is association with the loss of the Y chromosome.
Another possible mechanism of cooperation between AML1-ETO and KIT could rely on a potential direct interaction of AML1 with the KIT promoter. Several studies have shown that AML1-ETO acts as a dominant negative regulator of AML1 target genes. 9, 44 To our knowledge, no direct interactions between AML1 or AML1-ETO as transcription factors only.
For personal use at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From and the KIT gene have been reported yet, but it should be noted that the expression of the ETV6L-AML1 fusion protein in t(12;21) positive acute lymphoblastic leukemia led to an increase in primitive c-kit-positive multipotent progenitors in a murine bone marrow transplantation model. 45 In addition, Wang et al. 8 have identified 11 types of KIT mutations including 6 previously undescribed ones among 26/54 (48.1%) of cases with t(8;21). They could provide evidence that KIT seems to be the second but crucial genetic hit in AML1-ETO positive AML. These authors hypothesized that upregulation of KIT-protein may be an alternative mechanism to activation of KIT by mutation and this may explain the higher Kit expression in patients with t(8;21).
In the present study, we could show using in vitro systems that the transforming KIT-D816V mutation was susceptible to inhibition by PKC412 in contrast to imatinib and SU5614.
Receptor tyrosine kinases like KIT are able to activate complex intracellular signal transduction pathways upon ligand binding and dimerization by catalyzing the transfer of the γ-phosphoryl group of adenosine triphosphate (ATP) to tyrosine residues of adaptor and target proteins. 1, 46 Selective PTK inhibitors like imatinib and PKC412 that compete with ATP have been successfully used in the treatment of patients with acute and chronic myeloid leukemias. 32 We have shown that activating mutations in the activation loop of KIT (D816V) were strongly associated with AML1-ETO-positive AML and a poor clinical outcome. As described previously, the KIT-D816V mutant induced IL-3 independent growth in Ba/F3 cells and was resistant to the growth inhibitory activity of imatinib and SU5614. In contrast, the PTK inhibitor PKC412 that has been described to inhibit protein kinase C 
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